Objective To investigate the dynamic changes of pulmonary artery pressure in children with respiratory distress syndrome after noninvasive positive nasal pressure ventilation combined with pulmonary surfactant (PS). Methods 95 children with respiratory distress syndrome admitted to our hospital from February 2020 to April 2022 were randomly divided into two groups, 45 cases in the control group and 50 cases in the research group. The control group was treated with noninvasive positive nasal pressure ventilation, while the study group was treated with noninvasive positive nasal pressure ventilation combined with PS. The effects of different treatments on related indexes, pulmonary artery pressure, arterial blood gas indexes, serum cytokines, effective rate and complication rate were compared between the two groups, to analyze the value of combined treatment. Results Compared with the control group, the mechanical ventilation, oxygen therapy and hospitalization time in the study group were shorter (P < 0.05). Before treatment, there was no significant difference in pulmonary artery pressure between the two groups (P > 0.05). After treatment for 1,3,5 and 7 days, the pulmonary artery pressure in the two groups decreased, but compared with the control group, the change in the study group was more obvious (P < 0.05). Before treatment, there was no significant difference in arterial blood gas indexes between the two groups (P > 0.05). After treatment, PaO2 and SaO2 in both groups increased and PaCO2 decreased, but compared with the control group, the changes in the study group were more obvious (P < 0.05). There was no significant difference in arterial serum cytokines between the two groups before treatment (P > 0.05). After treatment, KL-6, MIF-1 and HMGB-1 in both groups decreased, but compared with the control group, the changes in the study group were more obvious (P < 0.05). Compared with the control group, the effective rate of the study group was higher (P < 0.05). Compared with the control group, the incidence of complications in the study group was lower (P < 0.05). Conclusion In the treatment of respiratory distress syndrome, the application of noninvasive positive nasal pressure ventilation combined with PS has an ideal effect, which is worth further popularization and application.
References
[1] Sweet, D. G., Carnielli, V., Greisen, G., Hallman, M., Ozek, E., Te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., Simeoni, U., Speer, C. P., Vento, M., Visser, G. H. A., Halliday, H. L. (2019) European consensus guidelines on the management of respiratory distress syndrome – 2019 update. Neonatology, 115(4), 432-450.
[2] Chi, M., Mei, Y. B., Feng, Z. C. (2018) A review on neonatal acute respiratory distress syndrome. Zhongguo Dang Dai Er Ke Za Zhi, 20(9), 724-728.
[3] Sardesai, S., Biniwale, M., Wertheimer, F., Garingo, A., Ramanathan, R. (2017) Evolution of surfactant therapy for respiratory distress syndrome: Past, present, and future. Pediatrics Research, 81(1-2), 240-248.
[4] Reynolds, P., Bustani, P., Darby, C., Fernandez Alvarez, J. R., Fox, G., Jones, S., Robertson, S. J., Vasu, V., Roehr, C. C. (2021) Less-invasive surfactant administration for neonatal respiratory distress syndrome: A consensus guideline. Neonatology, 118(5), 586-592.
[5] Cattel, F., Giordano, S., Bertiond, C., Lupia, T., Corcione, S., Scaldaferri, M., Angelone, L., De Rosa, F. G. (2021) Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury. Respiratory Physiology & Neurobiology, 288, 103645.
[6] Aldana-Aguirre, J. C., Pinto, M., Featherstone, R. M., Kumar, M. (2017) Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: A systematic review and meta-analysis. Archives of Disease in Childhood – Fetal & Neonatal Edition, 102(1), F17-F23.
[7] Bae, C. W., Kim, C. Y., Chung, S. H., Choi, Y. S. (2019) History of pulmonary surfactant replacement therapy for neonatal respiratory distress syndrome in Korea. Journal of Korean Medical Science, 34(25), e175.
[8] Huo, M. Y., Mei, H., Zhang, Y. H., Liu, C. Z., Hu, Y. N., Song, D. (2020) Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: A meta-analysis. Zhongguo Dang Dai Er Ke Za Zhi, 22(7), 721-727.
[9] Gupta, B. K., Saha, A. K., Mukherjee, S., Saha, B. (2020) Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation: A randomized controlled trial. European Journal of Pediatrics, 179(8), 1287-1293.
[10] Verder, H., Heiring, C., Schousboe, P. (2021) Surfactant therapy of respiratory distress syndrome. Ugeskrift for laeger, 183(44), V04210322.
[11] Herting, E., Härtel, C., Göpel, W. (2019) Less invasive surfactant administration (LISA): Chances and limitations. Archives of Disease in Childhood – Fetal & Neonatal Edition, 104(6), F655-F659.
[12] Kothe, T. B., Sadiq, F. H., Burleyson, N., Williams, H. L., Anderson, C., Hillman, N. H. (2020) Surfactant and budesonide for respiratory distress syndrome: An observational study. Pediatrics Research, 87(5), 940-945.
[13] Shin, J. E., Yoon, S. J., Lim, J., Han, J., Eun, H. S., Park, M. S., Park, K. I., Lee, S. M. (2020) Pulmonary surfactant replacement therapy for respiratory distress syndrome in neonates: A nationwide epidemiological study in Korea. Journal of Korean Medical Science, 35(32), e253.
[14] You, H., Huang, X. (2021) Effect of pulmonary surfactant on the prevention of neonatal respiratory distress syndrome in premature infants. American Journal of Translational Research, 13(4), 3642-3649.
[15] Sood, B. G., Cortez, J., Kolli, M., Sharma, A., Delaney-Black, V., Chen, X. (2019) Aerosolized surfactant in neonatal respiratory distress syndrome: Phase I study. Early Human Development, 134, 19-25.
[16] Niemarkt, H. J., Hütten, M. C., Kramer, B. W. (2017) Surfactant for respiratory distress syndrome: New ideas on a familiar drug with innovative applications. Neonatology, 111(4), 408-414. https://doi.org/10.1159/000458466
[17] Madney, Y. M., Esquinas, A. M., Saeed, H., Harb, H. S., Abdelrahim, M. E. A. (2020) Noninvasive surfactant use in the treatment of respiratory distress syndrome. Pediatric Critical Care Medicine, 21(10), 926-927.
[18] Liu, H. Q., Tong, X. M., Han, T. Y., Zhang, H., Guo, M., Zhang, X. F., Liu, X. J., Zhang, X., Zhang, M. T., Liu, F., Bao, L. S., Zheng, J., Tian, X. Y., Gao, Q., Zhang, W. X., Duan, Y., Sun, F. F., Guo, W., Li, L., Xiao, M., Liu, W. L., Jiang, R. (2020) Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: A multicenter clinical trial. Zhonghua Er Ke Za Zhi, 58(5), 374-380.
[19] Cummings, J. J., Gerday, E., Minton, S., Katheria, A., Albert, G., Flores-Torres, J., Famuyide, M., Lampland, A., Guthrie, S., Kuehn, D., Weitkamp, J. H., Fort, P., Abu Jawdeh, E. G., Ryan, R. M., Martin, G. C., Swanson, J. R., Mulrooney, N., Eyal, F., Gerstmann, D., Kumar, P., Wilding, G. E., Egan, E. A., & AERO-02 Study Investigators. (2020) Aerosolized calfactant for newborns with respiratory distress: A randomized trial. Pediatrics, 146(5), e20193967.
[20] Aziz, A., Ohlsson, A. (2020) Surfactant for pulmonary hemorrhage in neonates. Cochrane Database of Systematic Reviews, 2020(2), CD005254.
[21] Dani, C., Mosca, F., Vento, G., Tagliabue, P., Picone, S., Lista, G., Fanos, V., Pratesi, S., Boni, L. (2018) Effects of surfactant treatment in late preterm infants with respiratory distress syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 31(10), 1259-1266.
[22] Ho, J. J., Subramaniam, P., Davis, P. G. (2020) Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants. Cochrane Database of Systematic Reviews, 2020(10), CD002271.
[23] Jeon, G. W. (2019) Surfactant preparations for preterm infants with respiratory distress syndrome: Past, present, and future. Korean Journal of Pediatrics, 62(5), 155-161.
[24] Rong, Z., Mo, L., Pan, R., Zhu, X., Cheng, H., Li, M., Yan, L., Lang, Y., Zhu, X., Chen, L., Xia, S., Han, J., Chang, L. (2021) Bovine surfactant in the treatment of pneumonia-induced neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: A multicenter, randomized, assessor-blinded, placebo-controlled trial. European Journal of Pediatrics, 180(4), 1107-1115.
[25] Nguyen, T. L., Perlman, C. E. (2020) Sulforhodamine B and exogenous surfactant effects on alveolar surface tension under acute respiratory distress syndrome conditions. Journal of Applied Physiology, 129(6), 1505-1513.
Share and Cite
Xu, Y., Fan, C., Xu, H., Shao, Q. (2025) Dynamic Changes of Pulmonary Artery Pressure in Children with Respiratory Distress Syndrome after Noninvasive Positive Nasal Pressure Ventilation Combined with Pulmonary Surfactant (PS). Journal of Disease and Public Health, 1(1), 22-30.